INTRODUCTION

Ganglioneuromas (GNs) are benign tumors that originate from neural crest cells, composed mainly of mature ganglion cells. These tumors, which are usually hormonally silent, tend to be discovered incidentally on imaging tests and occur along the paravertebral sympathetic chain, from the neck to the pelvis and occasionally in the adrenal medulla. Rarely, GNs secrete catecholamines.1 Adrenal GNs occur most frequently in the fourth and fifth decades of life, whereas GNs of the retroperitoneum and posterior mediastinum are usually encountered in younger adults.2 Adrenal GNs are commonly hormonally silent and asymptomatic; even when the lesion is of substantial size.3

We report an incidentally detected asymptomatic case of an adrenal ganglioneuroma with mildly elevated urinary catecholamine levels in an elderly male. After preoperative alpha blockade, the patient underwent open right adrenalectomy. Upon microscopic examination, the right adrenal mass proved to be a ganglioneuroma, maturing type and the immunohistochemistry examination showed immunoreactivity to synaptophysin, chromogranin, and CD 56, while S100 was strongly positive at the Schwannian stroma. Following resection, catecholamine levels normalized, confirming the resected right adrenal ganglioneuroma as the source of the catecholamine excess. This case represents a rare presentation of catecholamine-secreting adrenal ganglioneuroma in the elderly.

Key words: adrenal glands, catecholamine, ganglioneuroma

CASE

A 72-year-old man was referred to our endocrine outpatient clinic for an incidentally detected right-sided adrenal mass following a computed tomography angiography of bilateral lower limbs done for workup of critical limb ischemia measuring 121 mm x 146 mm x 141 mm with an absolute washout of -150% and relative washout of -34%. There was no evidence of metastatic disease and no obvious invasion into adjacent structures. The patient denied any paroxysmal symptoms and showed no clinical signs, except for hypertension for 20 years, well-controlled with a single agent. His urinary epinephrine (37.1 µg/day, normal range: 1.7-22.4 µg/day), norepinephrine (105.1 µg/day, normal range: 12.1-85.5 µg/day), and dopamine (587 mg/day, normal range: 64-400 mg/day) were all mildly elevated. Urinary HVA and VMA were not available.

From the laboratory and imaging findings, the tumor was presumed to be a pheochromocytoma with suspected malignant potential.

The patient underwent preoperative alpha-adrenergic blockade with phenoxybenzamine two weeks prior to surgery followed by beta-blockade. The patient underwent open right adrenalectomy under general anesthesia. He had profound hemodynamic fluctuations during the operation and required vasopressor support for less than 24 hours postoperatively. He was discharged well on postoperative day 12.

On microscopic examination, the right adrenal mass proved to be a ganglioneuroma (maturing type) and the immunohistochemistry examination showed immunoreactivity to synaptophysin, chromogranin, and CD 56, while S100 was strongly positive at the Schwannian stroma. Following resection, catecholamine levels normalized, confirming the resected right adrenal ganglioneuroma as the source of the catecholamine excess. This case represents a rare presentation of catecholamine-secreting adrenal ganglioneuroma in the elderly.
stoma and spindle cells. No mitosis was seen. Gold to brownish pigments were also seen in some neoplastic cells. No atypia, necrosis, or capsular breach was observed. No ganglioneuroblastic component or evidence of malignancy was seen. The immunohistochemistry examination showed immunoreactivity to synaptophysin, chromogranin, and CD 56 while S100 is strongly positive at the Schwannian stroma. They are negative for Pan Ck and GFAP.

**DISCUSSION**

Ganglioneuromas are rare, benign, well-differentiated neural crest tumors arising in the paravertebral sympathetic chain, and are classically non-secretory and clinically asymptomatic. Most ganglioneuromas are diagnosed incidentally on imaging. Patients may also present with non-specific symptoms such as back or abdominal pain due to tumor mass effect. As with all incidental adrenal masses, a hormonal workup should be performed to determine the etiology of the tumor. Assessment should include evaluation of catecholamine or metanephrine levels, screening for cortisol excess, and measurement of plasma renin activity and aldosterone concentration.

Ganglioneuromas are histologically benign lesions and can be classified into two main categories. The “mature type” GNs comprise of mature Schwann cells, ganglion cells, and perineural cells within a fibrous stroma whilst completely lacking neuroblasts and mitotic figures. The “maturing type” GNs consist of similar cellular populations with miscellaneous maturation degrees, ranging from fully mature cells to neuroblasts.

**Table 1. Differences in characteristics between pheochromocytoma, neuroblastoma, and ganglioneuroma**

| Characteristics | Pheochromocytoma | Neuroblastoma | Ganglioneuroma |
|-----------------|------------------|---------------|---------------|
| Location        | Adrenal          | Adrenal, Paraspinal | Adrenal, Paravertebral sympathetic chain |
| Origin          | Chromaffin cells | Neuroblasts    | Neural crest cells |
| Urinary HVA, VMA, Metanephrines | Metanephrines more specific | Predominantly HVA and VMA | Metanephrines, HVA, and VMA (Rare) |
| HVA – Homovanillic acid; VMA – Vanillylmandelic acid | | |

**Figure 1.** Coronal Section Contrast-Enhanced CT Adrenal images in portovenous phase showing a large heterogeneous enhancing right adrenal mass with no calcification or fat component within (arrow). The density of the mass on the plain study is 41 HU, in portovenous phase 53 HU, and delayed study 71 HU.

**Figure 2.** Macroscopic findings. (A) Right adrenalectomy specimen: Large, well-circumscribed lobular mass weighing 1167 g and measuring 155 × 140 × 85 mm. The mass is smooth and shiny on the outer surface with some attached fatty tissues. Fine vessels are seen on its brownish-grey surface; (B) Right adrenalectomy specimen. Cut surface showing soft dark brownish multicystic areas with extensive hemorrhage. The cystic spaces range from 5-20 mm in diameter.
Although ganglioneuromas are thought to have no to low metabolic activity, several previous studies have reported high concentrations of catecholamines or MIBG uptake in intra- and extra-adrenal ganglioneuromas.\(^8,9\)

It has been reported that up to 30% of patients with GNs may have elevated plasma and urinary catecholamine levels without exhibiting any symptoms of catecholamine excess.\(^10\) Our patient was asymptomatic and definitely required surgical intervention for the large adrenal mass, however, without adequate preoperative preparation, he would have been at risk for potentially fatal complications of the surgery. Thus, it is prudent to thoroughly investigate suspicious adrenal masses biochemically to avoid missing excess catecholamine secretion from the adrenal mass as significant morbidity and mortality can ensue intraoperatively if the patient is not adequately prepared for surgery. This patient made a remarkable recovery despite the stormy intraoperative and postoperative complications that ensued.

![Figure 3. Histopathology of the mass. (A) Ganglioneuroma. The neoplastic cells are arranged in clusters set in loose fibrocollagenous stroma (H&E, 4x); (B) Ganglioneuroma. Neoplastic cells exhibiting mature ganglion cells with eccentric nuclei, prominent nucleoli, and abundant eosinophilic cytoplasm with surrounding Schwannian stroma and spindle cells (H&E, 20x). Ganglioneuroma. Immunohistochemical stains show that the neoplastic cells are positive for (C) Synaptophysin, (D) Chromogranin, (E) CD56, and (F) negative for GFAP.](image-url)
Composite pheochromocytoma–ganglioneuroma tumors are different, rare entities, consisting of both endocrine and neural components. Embryologically, both chromaffin and ganglion cells are derived from neural crest cells and migrate to somatic areas. Immunohistochemically, the individual components of these tumors resemble their normal counterparts or pure tumors of the same type. Synaptophysin and chromogranin are strongly and diffusely positive in pheochromocytoma, while weak or focal in ganglioneuroma or neuroblasts. Staining for S-100 protein identifies spindle-shaped Schwannian cells and sustentacular cells while neurofilament only stains the neural part of the composite tumor.

Histologically, the endocrine component is that of a typical pheochromocytoma, whereas the neuronal component is characterized by mixed areas of ganglioneuroma, neuroblastoma, or ganglioneuroblastoma. Our patient’s histopathological examination did not reveal any chromaffin cells, excluding a pheochromocytoma–ganglioneuroma.

CONCLUSION

This case illustrates that ganglioneuromas can grow to a significant size and present incidentally. They can be asymptomatic, as in our patient, who had a catecholamine secreting, histologically and immunohistochemistry confirmed maturing type of adrenal ganglioneuroma.

Following resection, catecholamine levels normalized, confirming the resected right adrenal ganglioneuroma as the source of the catecholamine excess. The patient made a remarkable recovery subsequently.

Ethical Consideration

Patient consent was obtained before the submission of the manuscript.

Statement of Authorship

All authors certified fulfillment of ICMJE authorship criteria.

Author Disclosure

The authors declared no conflict of interest.

Funding Source

None.

References

1. Chan OTM, Haghhighi P. Hamartomatic polyps of the colon: Ganglioneuromas, stromal, and lipomatous. Arch Pathol Lab Med. 2006;130(10):1561-6. PMID: 17060203. https://doi.org/10.5878/2006-130-1561-HPOTCG.
2. Qing Y, Bin X, Jian W, et al. Adrenal ganglioneuromas: A 10-year experience in a Chinese population. Surgery. 2010;147(6):854-60. PMID: 2060552. https://doi.org/10.1016/j.surg.2009.11.010.
3. Allende DS, Hansel DE, Macklemen GT. Ganglioneuroma of the adrenal gland. J Urol. 2009;182(5):714-8. PMID: 19593919. https://doi.org/10.1016/j.juro.2009.05.036.
4. Graham-Pole J, Salmi T, Anton AH, Abramowsky C, Gross S. Tumor and urine catecholamines (CATs) in neurogenic tumors. Correlations with other prognostic factors and survival. Cancer. 1983;51(5):834-9. PMID: 6821849.
5. Rha SE, Byun JY, Jung SE, et al. Neurogenic tumors in the abdomen: Tumor types and imaging characteristics. Radiographics 2003;23(1):29-43. PMID: 12533638. https://doi.org/10.1148/rg.231025650.
6. Jaulim A, Nkwam N, Williams S. Mature ganglioneuroma of the adrenal gland as a new rare cause of visible haematuria: A case report & literature review. Int J Surg Case Rep. 2015;14:1-3. PMID: 26196309. PMCID: PMC4573211. https://doi.org/10.1016/j.ijscr.2015.06.027.
7. Lonergan GJ, Schwab CM, Suarez ES, Carlson CL. Neuroblastoma, ganglioneuroblastoma, and ganglioneuroma: Radiologic-pathologic correlation. Radiographics. 2002;22(4):911-54. PMID: 12110723. https://doi.org/10.1148/radiographics.22.4.9215911.
8. Camelo M, Aponte LF, Lugo-Vicente H. Dopamine-secreting adrenal ganglioneuroma in a child: Beware of intraoperative rebound hypertension. J Pediatr Surg. 2012;47(9):E29-32. PMID: 22974632. https://doi.org/10.1016/j.jpedsurg.2012.04.017.
9. Koch CA, Brouwers FM, Rosenblatt K, et al. Adrenal ganglioneuroma in a patient presenting with severe hypertension and diarrhea. Endocr Relat Cancer. 2003;10(1):99-107. PMID: 12653673. https://doi.org/10.1677/erc.0.010009.
10. Geoerger B, Hero B, Harms D, Grebe J, Scheidhauer K, Berthold F. Metabolic activity and clinical features of primary ganglioneuromas. Cancer. 2001;91(10):1905-13. PMID: 11346873.
11. Weston JA. The migration and differentiation of neural crest cells. Adv Morphogr. 1970;8:841-114. PMID: 4906187. https://doi.org/10.1016/j.amorph.2009-01-28608-9.00006-5.
12. Mahajan H, Lee D, Sharma R, et al. Composite pheochromocytoma-ganglioneuroma, an uncommon entity: Report of two cases. Pathology. 2010; 42(3):295-8. PMID: 20350228. https://doi.org/10.3109/00313020103636451.

Authors are required to accomplish, sign and submit scanned copies of the JAFES Author Form consisting of: (1) Authorship Certification, that authors contributed substantially to the work, that the manuscript has been read and approved by all authors, and that the requirements for authorship have been met by each author; (2) the Author Declaration, that the article represents original material that is not being considered for publication or has not been published or accepted for publication elsewhere, that the article does not infringe or violate any copyrights or intellectual property rights, and that no references have been made to predatory/suspected predatory journals; (3) the Author Contribution Disclosure, which lists the specific contributions of authors; (4) the Author Publishing Agreement which retains author copyright, grants publishing and distribution rights to JAFES, and allows JAFES to apply and enforce an Attribution-Non-Commercial Creative Commons user license; and (5) the Conversion to Visual Abstracts (*optional for original articles only) to improve dissemination to practitioners and lay readers. Authors are also required to accomplish, sign, and submit the signed ICMJE form for Disclosure of Potential Conflicts of Interest. For original articles, authors are required to submit a scanned copy of the Ethics Review Approval of their research as well as registration in trial registries as appropriate. For manuscripts reporting data from studies involving animals, authors are required to submit a scanned copy of the Institutional Animal Care and Use Committee approval. For Case Reports or Series, and Images in Endocrinology, consent forms, are required for the publication of information about patients; otherwise, appropriate ethical clearance has been obtained from the institutional review board. Articles and any other material published in the JAFES represent the work of the author(s) and should not be construed to reflect the opinions of the Editors or the Publisher.